Stay updated on Dupilumab in COPD Clinical Trial
Sign up to get notified when there's something new on the Dupilumab in COPD Clinical Trial page.

Latest updates to the Dupilumab in COPD Clinical Trial page
- Check3 days agoChange DetectedThe Publications section now lists the final Chest article (July 2026) for the post hoc analysis of BOREAS and NOTUS, replacing the earlier online-ahead-of-print citation. This update provides final publication details without altering study results or participant information.SummaryDifference0.0%

- Check10 days agoChange DetectedPublications section updated with a new citation for a pooled analysis of two Phase 3 dupilumab COPD trials, listing the authors and DOI. The revision version is updated to v3.6.3 and the prior v3.6.1 revision is removed.SummaryDifference0.0%

- Check17 days agoChange DetectedThe page revision label was updated from v3.6.0 to v3.6.1, indicating a new version of the record; this update reflects metadata changes rather than substantive study information.SummaryDifference0.0%

- Check31 days agoChange DetectedThe page now shows that it is no longer looking for participants, signaling enrollment is closed. It also adds reader-focused resources such as How to Read a Study Record, Common Questions, and How to Join a Study, while removing the Intervention/Treatment header and a previously published citation.SummaryDifference0.1%

- Check38 days agoChange DetectedThe page now shows Revision: v3.5.5, replacing the previous Revision: v3.5.4. This marks a minor version label update rather than a substantive change to the page content.SummaryDifference0.0%

- Check53 days agoChange DetectedThe page now shows a new platform revision label: v3.5.4 replaces the previous v3.5.3. This reflects a system update rather than a change to the study details or page content.SummaryDifference0.0%

Stay in the know with updates to Dupilumab in COPD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dupilumab in COPD Clinical Trial page.